Skip to main content
Weight Lossmetabolicheartdigestive

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

By the Peptide Dossier Editorial TeamUpdated How we source

Semaglutide is a GLP-1 receptor agonist used in product-specific diabetes, weight-management, cardiovascular, kidney and MASH indications. Weekly injections and daily tablets contain the same active molecule but have different labels and instructions.

Quick Facts

Class:GLP-1 receptor agonist
Evidence context:Large SUSTAIN, STEP, SELECT and FLOW randomized programs support product- and population-specific outcomes.
Product context:FDA-approved semaglutide products have distinct diabetes, weight, cardiovascular, kidney and MASH indications and formulation-specific instructions.

What is semaglutide?

Semaglutide is a modified synthetic analog with about 94% structural similarity to human GLP-1. A fatty-acid side chain promotes albumin binding and reduces renal clearance; resistance to rapid degradation also helps extend elimination to about a week. Novo Nordisk products include weekly Ozempic injection for type 2 diabetes, Wegovy injection or daily tablets for relevant weight-management indications, and Rybelsus daily diabetes tablets. Formulations are not automatically dose interchangeable.

Sources: [1]

How does semaglutide work?

GLP-1 signaling promotes insulin release when glucose is elevated, reduces glucagon, slows gastric emptying and reduces hunger through appetite-related brain pathways. This combines glucose control with lower food intake; isolated hypoglycemia risk is low, but insulin or sulfonylurea combinations change that risk.

STEP 1 randomized 1,961 adults with overweight/obesity without diabetes. With lifestyle intervention, 2.4 mg weekly produced mean weight change −14.9% at 68 weeks versus −2.4% placebo, using an estimand including discontinuation or rescue. SELECT enrolled 17,604 adults with established cardiovascular disease and overweight/obesity without diabetes and found 20% lower major-cardiovascular-event risk. FLOW studied type 2 diabetes with chronic kidney disease and found lower kidney-progression/cardiovascular-death risk, supporting a 2025 indication.

Sources: [2], [4], [6], [7], [8]

Is it FDA-approved?

Ozempic received diabetes approval in 2017, later cardiovascular indications, and in January 2025 kidney-progression/cardiovascular-death risk reduction for adults with type 2 diabetes and CKD. In January 2026, one Rybelsus tablet formulation was renamed Ozempic tablets.

Rybelsus was approved in 2019 as the first oral GLP-1 medicine for type 2 diabetes; October 2025 added cardiovascular-risk reduction in high-risk adults with diabetes. Wegovy received chronic weight-management approval in June 2021, specified cardiovascular-risk reduction in March 2024 and noncirrhotic MASH with moderate-to-advanced fibrosis in August 2025. Daily Wegovy tablets were approved in December 2025; the higher 7.2 mg Wegovy HD dose received accelerated approval in March 2026. Each indication must be tied to its actual product/formulation.

Sources: [5]

What is semaglutide prescribed for?

Ozempic and Rybelsus support glycemic control alongside diet and exercise in type 2 diabetes. Wegovy weight-management criteria include adult BMI at least 30, or at least 27 with a weight-related condition such as hypertension or dyslipidemia, and product-specific adolescent obesity use from age 12.

Other indications address cardiovascular events in defined populations, kidney disease with type 2 diabetes and noncirrhotic MASH with fibrosis. Semaglutide does not treat type 1 diabetes. Personal/family medullary thyroid carcinoma, MEN2 and serious semaglutide allergy are contraindications.

What are the side effects?

Common effects include nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite, dyspepsia/heartburn, fatigue, headache and dizziness, often during escalation. Tingling or burning skin sensations are reported particularly at the highest Wegovy dose.

The boxed C-cell-tumor warning is based on rodents, with uncertain human relevance. Important risks include pancreatitis, gallbladder problems/stones, dehydration-related acute kidney injury, worsening diabetic retinopathy, hypoglycemia with insulin or sulfonylureas, delayed-emptying-related aspiration during anesthesia and serious allergic reactions.

SELECT: events, heart-failure subgroups and mediation

SELECT participants were aged at least 45 with BMI at least 27 and preexisting cardiovascular disease, without diabetes. Over mean 39.8 months, major events occurred in 6.5% versus 8.0%: HR 0.80, 95% CI 0.72–0.90. A 4,286-person heart-failure subanalysis reported MACE reductions in reduced-ejection-fraction (HR 0.65) and preserved-ejection-fraction (HR 0.69) subgroups. Another analysis estimated 33% of cardiovascular benefit was mediated through waist-circumference reduction. A modeled mediation estimate is not proof of a single causal mechanism for every patient.

Sources: [3], [9], [10], [11]

Maintenance, withdrawal and actual product instructions

The exploratory STEP 1 extension followed 327 participants after semaglutide and lifestyle support stopped; the treated group regained about two-thirds of its earlier loss within a year. In STEP 4, after a 20-week 2.4 mg run-in, continued semaglutide produced an additional 7.9% loss while switching to placebo produced 6.9% regain from week 20 to 68.

Use the label for the exact formulation and indication. Current Wegovy labeling includes tablets and injection doses beyond the original 2.4 mg regimen. Ozempic missed-dose instructions should not be applied indiscriminately to Wegovy, and dose changes belong with the treating clinician.

Sources: [12], [13]

Glycemic studies and comparative interpretation

STEP 8 directly randomized 338 participants for 68 weeks: semaglutide weight change was −15.8% versus −6.4% with liraglutide, a −9.4-point difference. SUSTAIN FORTE enrolled 961 adults with type 2 diabetes over 40 weeks; semaglutide 2.0 mg lowered HbA1c by 2.2 points and weight by 6.9 kg, while 1.0 mg lowered HbA1c by 1.9 points.

A 2023 meta-analysis of 17 RCTs and 14,940 participants estimated a placebo-adjusted HbA1c reduction of 1.36 points for subcutaneous 1.0 mg (95% CI −1.59 to −1.13), without an increase in serious adverse events.

SURMOUNT-1 separately studied 2,539 participants for 72 weeks and reported −20.9% at tirzepatide 15 mg, compared with −14.9% at semaglutide 2.4 mg in the separate 1,961-person, 68-week STEP 1. This is a cross-trial comparison. A 2024 network analysis of 28 diabetes RCTs and 23,622 participants estimated placebo-adjusted HbA1c reductions of 1.96 points for tirzepatide 15 mg versus 1.59 for semaglutide 2.0 mg, judged comparable by the authors, and weight reductions of 9.57 versus 4.97 kg. Indirect estimates and different populations are not a guarantee of individual superiority.

Sources: [14], [15], [16], [17], [18]

References and further reading

This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .

  1. accessdata.fda.govWhat is semaglutide?Cited in: What is semaglutide?
  2. 10.1056/NEJMoa2032183How does semaglutide work?Cited in: How does semaglutide work?
  3. 10.1056/NEJMoa2307563SELECT: events, heart-failure subgroups and mediationCited in: SELECT: events, heart-failure subgroups and mediation
  4. jamanetwork.comHow does semaglutide work?Cited in: How does semaglutide work?
  5. ajmc.comIs it FDA-approved?Cited in: Is it FDA-approved?
  6. 10.1056/NEJMoa2403347How does semaglutide work?Cited in: How does semaglutide work?
  7. dailymed.nlm.nih.govHow does semaglutide work?Cited in: How does semaglutide work?
  8. pubmed.ncbi.nlm.nih.govHow does semaglutide work?Cited in: How does semaglutide work?
  9. pubmed.ncbi.nlm.nih.govSELECT: events, heart-failure subgroups and mediationCited in: SELECT: events, heart-failure subgroups and mediation
  10. pubmed.ncbi.nlm.nih.govSELECT: events, heart-failure subgroups and mediationCited in: SELECT: events, heart-failure subgroups and mediation
  11. pubmed.ncbi.nlm.nih.govSELECT: events, heart-failure subgroups and mediationCited in: SELECT: events, heart-failure subgroups and mediation
  12. pubmed.ncbi.nlm.nih.govMaintenance, withdrawal and actual product instructionsCited in: Maintenance, withdrawal and actual product instructions
  13. pubmed.ncbi.nlm.nih.govMaintenance, withdrawal and actual product instructionsCited in: Maintenance, withdrawal and actual product instructions
  14. pubmed.ncbi.nlm.nih.govGlycemic studies and comparative interpretationCited in: Glycemic studies and comparative interpretation
  15. pubmed.ncbi.nlm.nih.govGlycemic studies and comparative interpretationCited in: Glycemic studies and comparative interpretation
  16. pubmed.ncbi.nlm.nih.govGlycemic studies and comparative interpretationCited in: Glycemic studies and comparative interpretation
  17. pubmed.ncbi.nlm.nih.govGlycemic studies and comparative interpretationCited in: Glycemic studies and comparative interpretation
  18. pubmed.ncbi.nlm.nih.govGlycemic studies and comparative interpretationCited in: Glycemic studies and comparative interpretation
  19. www.novo-pi.com — additional reading

Frequently Asked Questions About Semaglutide

They contain semaglutide, but their indications, formulations and instructions differ. Use the label for the exact prescribed product.

No. Current Wegovy prescribing information includes oral tablets. Older descriptions of an oral formulation as only in development are out of date.

In adults with overweight or obesity without diabetes, the mean weight reduction with semaglutide 2.4 mg was 14.9% at 68 weeks, compared with 2.4% for placebo, alongside lifestyle intervention. This primary estimand assessed effects regardless of treatment discontinuation or rescue interventions.

No. Outcomes depend on the population, formulation, dose, duration and individual response.

It activates GLP-1 receptors, reduces hunger/food intake and slows gastric emptying. Albumin binding and degradation resistance extend action to roughly one week; the 68-week STEP 1 group mean was −14.9% versus −2.4% placebo, not a personal forecast.

In 17,604 adults aged at least 45 with BMI at least 27 and established cardiovascular disease but no diabetes, 2.4 mg weekly reduced major cardiovascular events: HR 0.80, 95% CI 0.72–0.90, over mean 39.8 months. Subgroup and mediation analyses require their specific context.

In a selected STEP 1 extension group, about two-thirds of prior weight loss returned over the year after drug and lifestyle intervention stopped. STEP 4 likewise found regain after switching to placebo. Individual trajectories vary.

Ozempic, Wegovy and Rybelsus have product- and formulation-specific indications and instructions, including injection and oral presentations. They are not automatically interchangeable schedules.

The head-to-head STEP 8 trial in 338 participants over 68 weeks reported −15.8% weight change with semaglutide versus −6.4% with liraglutide, a −9.4 percentage-point difference. This direct comparison differs from comparing separate trials.

SUSTAIN FORTE found reductions of 2.2 percentage points at 2.0 mg versus 1.9 points at 1.0 mg over 40 weeks. A separate 17-trial meta-analysis estimated a −1.36-point placebo-adjusted effect for subcutaneous 1.0 mg. Dose, comparator and population matter.

Semaglutide targets GLP-1; tirzepatide targets GLP-1 and GIP. Separate obesity trials and network analyses report different group outcomes but do not themselves constitute a matched head-to-head comparison. Semaglutide also has SELECT cardiovascular evidence in people without diabetes.

Related Peptides

Continue exploring Semaglutide

Search all related references →

Our library review is ongoing. Read how we evaluate evidence or report a correction.

Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.